[HTML][HTML] Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
SS Neelapu, FL Locke, NL Bartlett… - … England Journal of …, 2017 - Mass Medical Soc
Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …
[PDF][PDF] Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma
NL Bartlett, A Ghobadi - 2017 - digitalcommons.wustl.edu
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma Page 1
Washington University School of Medicine Digital Commons@Becker Open Access Publications …
Washington University School of Medicine Digital Commons@Becker Open Access Publications …
[PDF][PDF] Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma
NL Bartlett, A Ghobadi - N Engl J Med, 2017 - core.ac.uk
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma Page 1
Washington University School of Medicine Digital Commons@Becker Open Access Publications …
Washington University School of Medicine Digital Commons@Becker Open Access Publications …
[HTML][HTML] Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis… - uclmbphdjournalclub.wordpress …
Background: Axicatbagene Ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen
receptor (CAR) T-cell therapy that has previously been through a phase 1 clinical trial. CAR …
receptor (CAR) T-cell therapy that has previously been through a phase 1 clinical trial. CAR …
[HTML][HTML] Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
SS Neelapu, FL Locke, NL Bartlett… - The New England …, 2017 - scholarship.miami.edu
Abstract Immunotherapy, Adoptive Interleukins-blood Humans Middle Aged Receptors,
Antigen, T-Cell-therapeutic use Male Survival Rate Biomarkers-blood T-Lymphocytes …
Antigen, T-Cell-therapeutic use Male Survival Rate Biomarkers-blood T-Lymphocytes …
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
SS Neelapu, FL Locke, NL Bartlett… - The New England …, 2017 - escholarship.org
BackgroundIn a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma
SS Neelapu, FL Locke, NL Bartlett… - New England Journal …, 2017 - profiles.wustl.edu
BACKGROUND In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-
CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with …
CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with …
[HTML][HTML] Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
SS Neelapu, FL Locke, NL Bartlett… - The New England …, 2017 - ncbi.nlm.nih.gov
BACKGROUND In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-
CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with …
CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with …
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
SS Neelapu, FL Locke, NL Bartlett… - The New England …, 2017 - iro.uiowa.edu
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric
antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell …
antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell …
[引用][C] Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis… - New England Journal …, 2017 - cir.nii.ac.jp